Skip to main content
. 2017 Feb 21;19:19. doi: 10.1186/s13058-017-0811-z

Table 3.

Age-adjusted HRs and 95% CIs for the association between lifetime recreational physical activity and 15-year all-cause and breast cancer-specific mortality stratified by gene methylation status (methylated vs. unmethylated tumors) among 803 women diagnosed with a first primary breast cancer and with available gene promoter methylation data, Long Island Breast Cancer Study Project

All-cause mortality Breast cancer-specific mortality
Unmethylated Methylated Unmethylated Methylated
Gene promoter and RPA categories Deaths/cases–n HR 95% CI Deaths/cases–n HR 95% CI Deaths/cases–n HR 95% CI Deaths/cases–n HR 95% CI
APC
 Inactive 38/88 1.00 Reference 49/93 1.00 Reference 14/88 1.00 Reference 24/93 1.00 Reference
 <6.36 h/week 54/173 0.83 (0.54–1.26) 38/135 0.46 (0.30–0.70) 21/173 0.64 (0.32–1.27) 16/135 0.35 (0.18–0.65)
 ≥6.36 h/week 40/131 0.71 (0.45–1.10) 46/136 0.60 (0.40–0.80) 16/131 0.63 (0.31–1.29) 26/136 0.58 (0.33–1.02)
p-interaction 0.038 0.138
BRCA1
 Inactive 35/79 1.00 Reference 56/118 1.00 Reference 9/79 1.00 Reference 30/118 1.00 Reference
<6.36 h/week 33/128 0.60 (0.37–0.97) 63/192 0.68 (0.47–0.98) 12/128 0.60 (0.25–1.44) 27/192 0.47 (0.28–0.79)
  ≥ 6.36 h/week 38/119 0.73 (0.46–1.16) 56/167 0.68 (0.47–0.99) 15/119 0.90 (0.40–2.07) 29/167 0.58 (0.35–0.96)
p-interaction 0.485 0.341
CDH1
 Inactive 69/157 1.00 Reference 11/16 1.00 Reference 30/157 1.00 Reference <5/16 Not estimated
  < 6.36 h/week 88/283 0.73 (0.54–1.01) <5/15 Not estimateda 35/283 0.54 (0.33–0.89) <5/15 Not estimated
 ≥6.36 h/week 81/243 0.77 (0.56–1.06) <5/12 Not estimated 37/243 0.69 (0.43–1.12) <5/12 Not estimated
p-interaction Not estimated Not estimated
CCND2
 Inactive 55/135 1.00 Reference 25/38 1.00 Reference 22/135 1.00 Reference 12/38 1.00 Reference
  < 6.36 h/week 76/244 0.82 (0.58–1.17) 15/54 0.30 (0.16–0.57) 34/244 0.73 (0.43–1.25) <5/54 not estimated
 ≥6.36 h/week 61/202 0.75 (0.52–1.08) 24/53 0.56 (0.32–0.99) 28/202 0.73 (0.42–1.28) 11/53 0.47 (0.21–1.08)
p-interaction 0.004 Not estimated
DAPK
 Inactive 69/149 1.00 Reference 11/24 1.00 Reference 29/149 1.00 Reference 5/24 1.00 Reference
  < 6.36 h/week 78/259 0.66 (0.47–0.91) 13/39 0.71 (0.32–1.60) 31/259 0.50 (0.30–0.83) 5/39 0.52 (0.15–1.80)
 ≥6.36 h/week 70/216 0.67 (0.48–0.94) 15/39 0.92 (0.42–2.00) 29/216 0.58 (0.34–0.96) 10/39 1.04 (0.36–3.05)
p-interaction 0.467 0.247
ESR1
 Inactive 51/104 1.00 Reference 40/91 1.00 Reference 19/104 1.00 Reference 20/91 1.00 Reference
  < 6.36 h/week 53/178 0.58 (0.39–0.85) 42/138 0.73 (0.47–1.13) 23/178 0.52 (0.28–0.96) 16/138 0.46 (0.24–0.89)
 ≥6.36 h/week 49/155 0.60 (0.41–0.89) 45/129 0.82 (0.54–1.26) 21/155 0.57 (0.30–1.05) 23/129 0.74 (0.40–1.35)
p-interaction 0.298 0.353
GSTP1
 Inactive 47/121 1.00 Reference 33/52 1.00 Reference 19/121 1.00 Reference 15/52 1.00 Reference
  < 6.36 h/week 64/220 0.76 (0.52–1.11) 27/78 0.51 (0.30–0.85) 26/220 0.65 (0.36–1.19) 10/78 0.31 (0.14–0.70)
 ≥6.36 h/week 54/182 0.73 (0.49–1.07) 31/73 0.67 (0.41–1.11) 22/182 0.67 (0.36–1.24) 17/73 0.59 (0.29–1.18)
p-interaction 0.219 0.134
HIN
 Inactive 24/67 1.00 Reference 56/106 1.00 Reference 9/67 1.00 Reference 25/106 1.00 Reference
  < 6.36 h/week 36/113 1.01 (0.60–1.70) 55/185 0.51 (0.35–0.74) 15/113 0.89 (0.39–2.07) 21/185 0.36 (0.20–0.64)
 ≥6.36 h/week 29/88 1.05 (0.61–1.81) 56/167 0.55 (0.38–0.80) 12/88 0.96 (0.40–2.29) 27/167 0.52 (0.30–0.90)
p-interaction 0.016 0.066
P16
 Inactive 76/166 1.00 Reference 9/11 1.00 Reference 31/166 1.00 Reference 7/11 1.00 Reference
  < 6.36 h/week 88/293 0.66 (0.49–0.90) <5/9 Not estimated 35/293 0.52 (0.32–0.85) <5/9 Not estimated
 ≥6.36 h/week 82/245 0.71 (0.52–0.98) <5/10 Not estimated 38/245 0.70 (0.43–1.12) <5/10 Not estimated
p-interaction Not estimated Not estimated
PR
 Inactive 76/174 1.00 Reference 15/23 1.00 Reference 31/174 1.00 Reference 8/23 1.00 Reference
  < 6.36 h/week 87/292 0.66 (0.49–0.91) 9/28 0.75 (0.30–1.90) 32/292 0.50 (0.31–0.82) 7/28 0.67 (0.22–2.10)
 ≥6.36 h/week 80/245 0.71 (0.52–0.97) 14/41 0.79 (0.34–1.80) 36/245 0.71 (0.44–1.15) 8/41 0.55 (0.18–1.64)
p-interaction 0.893 0.226
RARB
 Inactive 52/114 1.00 Reference 28/59 1.00 Reference 18/114 1.00 Reference 16/59 1.00 Reference
  < 6.36 h/week 70/225 0.75 (0.52–1.08) 21/73 0.51 (0.29–0.89) 26/225 0.61 (0.33–1.13) 10/73 0.41 (0.19–0.91)
 ≥6.36 h/week 59/189 0.71 (0.49–1.03) 26/66 0.75 (0.44–1.28) 27/189 0.74 (0.41–1.34) 12/66 0.64 (0.30–1.35)
p-interaction 0.158 0.420
RASSF1A
 Inactive 8/25 1.00 Reference 72/148 1.00 Reference <5/25 Not estimated 31/148 1.00 Reference
  < 6.36 h/week 10/38 0.73 (0.29–1.88) 81/260 0.65 (0.47–0.90) 5/38 Not estimated 31/260 0.46 (0.28–0.75)
 ≥6.36 h/week 15/47 0.93 (0.39–2.21) 70/208 0.67 (0.48–0.94) 5/47 Not estimated 34/208 0.63 (0.39–1.03)
p-interaction 0.330 Not estimated
TWIST1
 Inactive 60/148 1.00 Reference 20/25 1.00 Reference 25/148 1.00 Reference 9/25 1.00 Reference
  < 6.36 h/week 78/257 0.81 (0.58–1.14) 13/41 0.25 (0.13–0.51) 32/257 0.67 (0.39–1.13) <5/41 Not estimated
 ≥6.36 h/week 72/214 0.87 (0.61–1.22) 13/41 0.28 (0.14–0.56) 30/214 0.78 (0.46–1.33) 9/41 0.29 (0.11–0.77)
p-interaction 0.001 Not estimated

a Point estimate was not calculated, because cell sizes were less than 5